Soligenix reports positive clinical results from synthetic hypericin compatibility study for CTCL

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Soligenix Inc. announced the results of its compatibility study evaluating HyBryte (synthetic hypericin) for the treatment of cutaneous T-cell lymphoma have been published in the Journal of the European Academy of Dermatology & Venereology Clinical Practice. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login